Research into psilocybin aging effects is accelerating, with preclinical studies pointing to neuroplasticity promotion, reduced neuroinflammation, and improvements in longevity biomarkers. The findings are genuinely interesting, but human data remains limited, and...
Research into psilocybin for end-of-life anxiety has produced some of the most compelling clinical data in psychedelic science. Landmark trials at Johns Hopkins and NYU found that a single guided psilocybin session produced significant, lasting reductions in anxiety,...
Ibogaine opioid treatment research has moved significantly forward in 2025 and 2026, with new clinical data, a landmark $50 million Texas state investment, and a federal executive order directing agencies to accelerate review. The evidence shows real potential for...
Executive burnout psychedelic therapy is moving from the research margins into serious clinical conversation. A growing body of peer-reviewed evidence suggests that psilocybin-assisted therapy can reduce burnout and depressive symptoms more durably than conventional...
Research on psilocybin alcohol use disorder treatment, including a landmark 2022 randomized controlled trial published in JAMA Psychiatry, has shown meaningful reductions in heavy drinking days compared to placebo. The findings are significant, but the research is...
Interest in psychedelics and creativity among executives has moved well beyond Silicon Valley. Neuroscientific research points to measurable changes in divergent thinking, cognitive flexibility, and problem-solving in the days and weeks following a supported...
